Newly developed agents such as anti-VEGF monoclonal antibody, PARP inhibitors, and immune checkpoint inhibitors have significantly improved the quality of life and oncologic outcomes for ovarian cancer patients [21]. Here, VEGFA is linked to ovarian carcinoma.